Poster, Podium & Video Sessions
Presentation Authors: Laurel Nightingale*, Minneapolis, MN, Michael Dumas, Indianapolis, IN, Raymond Ogagarue, Minneapolis, MN, Folakemi Odedina, Gainesville, FL, Christopher Warlick, Philipp Dahm, Minneapolis, MN
Introduction: Black men experience the highest prostate cancer burden in the United States and globally. One of the factors that may contribute to the slow progress in eliminating prostate cancer disparities among Black men is their underrepresentation in randomized controlled trials (RCTs) of new treatment modalities. We conducted this study to assess the current status of Black men's participation in RCTs for prostate cancer.
Methods: We performed a protocol-driven systematic review for all published prostate cancer RCTs over a 25-year time period (1991-2015) searching PUBMED. We only included RCTs of patients with an established diagnosis of prostate cancer and excluded studies of screening and diagnosis. For studies that resulted in multiple publications, only the initial study was included. We excluded secondary and subgroup analyses.
Results: We found 584 unique trials that met the inclusion criteria, which we analyzed by type of intervention, sample size, disease stage, number of sites, origin, type of funding, publication year, the year enrollment began, and whether the study reported the inclusion of Black men. The median sample size of all trials was 125.5 (IQR = 60-286.5) and the median number of sites was 5 (IQR = 1-22). One hundred and eleven of the 584 (19.0%) trials worldwide and 81 of 189 (42.9%) of trials conducted exclusively within the US reported the enrollment of Black men. Of those trials that reported the inclusion of Black men, the median percentage of the study population was 10.55% overall (IQR = 6.6%-19.8%) and 12.27% (IQR = 7.0%-21.2%) for studies based exclusively in the United States. Among the 111 trials that reported the racial composition of participants, the median number of Black patients was 20 (IQR = 8-37.5). In studies conducted exclusively within the US, the median number of black patients was 17 (IQR = 8-31).
Conclusions: Less than 1 in 5 studies globally and half of studies from the US reported the participation of Black men. We found no study that enrolled Black men exclusively or that prospectively stratified analysis based on race. There is a critical need for greater involvement and better reporting of Black men's participation in prostate cancer trials.
Source Of Funding: Departmental, NIH (U54MD008620)
University of Minnesota
Badrinath R. Konety, M.D., M.B.A., is Professor and Chair of the Department of Urology and holds the Dougherty Family Chair in Uro-Oncology as well as being the Director of the Institute for Prostate and Urologic Cancers and Associate Director for Clinical Affairs of the Masonic Cancer Center at the University of Minnesota.
Badrinath Konety, M.D., completed his residency and American Foundation for Urologic Disease Research Scholar fellowship at the University of Pittsburgh. He also received an MBA from the University of Pittsburgh Katz School of Business. Dr. Konety also completed his urologic oncology fellowship at Memorial Sloan Kettering Cancer Center.
He has authored or co-authored nearly 200 original publications and numerous book chapters as well as editing a text on bladder cancer. He has been and is principal or co-investigator on grants funded through the Department of Defense, National Institutes of Health, American Geriatrics Society and Center for Disease Control. He received the Jahnigen Career Development Scholar Award, and is an active member of numerous professional medical societies including the American Urological Association, the American College of Surgeons, Societe Internationale D’Urologie and the American Association of Genitourinary Surgeons. He is currently the President Elect of the SIU and Associate Editor of the Journal of Urology.
Thursday, May 11
8:00 AM – 8:05 AM
Saturday, May 13
8:20 AM – 8:30 AM
Sunday, May 14
3:05 PM – 3:30 PM
Monday, May 15
1:00 PM – 3:00 PM